Eiger BioPharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eiger BioPharmaceuticals generated cash of -$74,548,000, which is more than the previous year. Cash used in financing activities reached the amount of $41,000 last year. Net change in cash is therefore -$358,000.
Cash Flow
| 2014 | -29.25M | -61.18M | 96.97M |
|---|---|---|---|
| 2015 | -41.09M | 70.36M | -10.93M |
| 2016 | -37.97M | -4.19M | 65.14M |
| 2017 | -38.37M | 22.65M | 19.99M |
| 2018 | -42.67M | -29.08M | 100.98M |
| 2019 | -63.61M | -16.47M | 58.19M |
| 2020 | -63.18M | -44.78M | 97.46M |
| 2021 | -71.34M | 61.53M | 3.34M |
| 2022 | -83.01M | 9.63M | 76.95M |
| 2023 | -74.54M | 74.22M | 41K |
EIGR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 25.79M | 22.22M | 28.86M | 39.37M | 61.26M | 32.03M | 27.75M | 4.77M | 14.43M | 7.90M |
Operating activities | ||||||||||
Net income | -74.96M | -96.77M | -33.91M | -65.05M | -70.25M | -52.39M | -42.44M | -47.08M | -44.41M | -33.85M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 750K | 842K | 799K | 645K | 486K | 54K | 41K | 23K | 504K | 153K |
Stock-based compensation expense | 5.00M | 8.31M | 7.90M | 5.97M | 5.67M | 5.00M | 4.24M | 3.19M | 3.02M | 3.31M |
| Deferred income tax benefit | 5.00M | 8.31M | 7.90M | 5.97M | 5.67M | 5.00M | 4.24M | 3.19M | 3.02M | 3.31M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 84K | 828K | -2.57M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 1.62M | -1.36M | -2.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -6.83M | 1.15M | 3.23M | -1.89M | 584K | 2.64M | 544K | 699K | -4.26M | 2.93M |
Cash generated by operating activities | -74.54M | -83.01M | -71.34M | -63.18M | -63.61M | -42.67M | -38.37M | -37.97M | -41.09M | -29.25M |
Investing activities | ||||||||||
Purchases Of Investments | -19.38M | -75.10M | -84.64M | -128.29M | -96.26M | -57.19M | -24.52M | -34.15M | 0 | -90.65M |
Investments In Property Plant And Equipment | -234K | -340K | -48.73M | -258K | -475K | -142K | -44K | -58K | -235K | -739K |
Acquisitions Net | 0 | -9.97M | 46.49M | 44.52M | 15.99M | 0 | 0 | 28.01M | 0 | 0 |
Cash generated by investing activities | 74.22M | 9.63M | 61.53M | -44.78M | -16.47M | -29.08M | 22.65M | -4.19M | 70.36M | -61.18M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 71.40M | 3.34M | 0 | 53.19M | 0 | 19.8M | 50.33M | 826K | 95.02M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.17M | 0 | -7.66M |
Repayments of term debt | 0 | 6.56M | 0 | 0 | 4.96M | 0 | 0 | -14.75M | 5.97M | 0 |
Cash used in financing activities | 41K | 76.95M | 3.34M | 97.46M | 58.19M | 100.98M | 19.99M | 65.14M | -10.93M | 96.97M |
Net Change In Cash | -358K | 3.57M | -6.64M | -10.50M | -21.88M | 29.22M | 4.27M | 22.97M | 18.34M | 6.53M |
Cash at end of period | 25.44M | 25.79M | 22.22M | 28.86M | 39.37M | 61.26M | 32.03M | 27.75M | 32.77M | 14.43M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |